Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?

Related Experiment Video

Updated: Jun 3, 2026

Single-molecule Manipulation of G-quadruplexes by Magnetic Tweezers
08:28

Single-molecule Manipulation of G-quadruplexes by Magnetic Tweezers

Published on: September 19, 2017

Shankar Balasubramanian1, Laurence H Hurley, Stephen Neidle

  • 1Department of Chemistry, University of Cambridge, Cambridge CB21EW, UK. sb10031@cam.ac.uk

Nature Reviews. Drug Discovery
|April 2, 2011
PubMed

Insights

G-quadruplexes, unique DNA structures, show promise as cancer drug targets. Stabilizing these structures in oncogenes offers a novel strategy for anticancer therapies.

Area of Science:

  • Biochemistry and Molecular Biology
  • Genetics
  • Pharmacology

Background:

  • G-quadruplexes are non-canonical four-stranded DNA structures.
  • These structures are frequently found in gene promoter regions, particularly those of oncogenes.
  • G-quadruplexes are increasingly recognized as potential targets for therapeutic intervention.

Purpose of the Study:

  • To review the evidence supporting the presence and function of G-quadruplexes in gene promoters.
  • To discuss the potential of G-quadruplexes as therapeutic targets in oncology.
  • To highlight the progress in developing small-molecule ligands for G-quadruplex-based cancer therapy.

Main Methods:

  • Literature review and analysis of existing research on G-quadruplexes in gene promoters.
  • Examination of the structural and physicochemical properties of G-quadruplexes relevant to drug development.
  • Discussion of strategies for targeting G-quadruplexes with small-molecule ligands.

Main Results:

  • G-quadruplexes are prevalent in promoter regions and can regulate gene transcription.
  • The unique structural features of G-quadruplexes suggest they are druggable targets.
  • Structural diversity among G-quadruplexes offers potential for developing selective therapeutic agents.

Conclusions:

  • G-quadruplexes represent a promising class of therapeutic targets in cancer treatment.
  • Stabilization of G-quadruplexes in oncogene promoters can lead to transcriptional repression.
  • Development of small-molecule ligands targeting G-quadruplexes is an active and advancing area of anticancer drug discovery.

More Related Videos

Single-Molecule Fluorescence Visualization of DNA Polymerase Dynamics at G-Quadruplexes05:37

Single-Molecule Fluorescence Visualization of DNA Polymerase Dynamics at G-Quadruplexes

Published on: April 4, 2025

Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks12:19

Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks

Published on: November 10, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...